DEERFIELD, Ill., April 18, 2002 Results from the largest randomized controlled trial ever conducted among patients undergoing peritoneal dialysis (PD) demonstrate that PD, a flexible home-based dialysis therapy for people with end-stage renal disease (ESRD), may be a viable option for a greater range of patients and existing patients may be able to remain on therapy longer than would have been assumed from current practice guidelines.

It is estimated that more than one million people worldwide suffering from ESRD are treated with some form of dialysis therapy, 10 to 15 percent of whom rely on a flexible daily PD regimen. The study, conducted by leading researchers in Mexico under the auspices of the Mexican health-care authorities , and supported by Baxter Healthcare Corporation and its Mexico affiliate, appears in the May issue (Volume 13, Issue 5) of the peer-reviewed publication, Journal of the American Society of Nephrology (JASN).

This is a pivotal study for the nephrology community worldwidefor both doctors and patients, said Salim Mujais, M.D., vice president of Global Medical Affairs for Baxters Renal business, and ADEMEX (Adequacy of Peritoneal Dialysis in Mexico) study author. The findings challenge existing treatment recommendations for PD, which may allow for greater flexibility in prescribing the therapy and potentially enable more patients to benefit from it.

Study Results
The ADEMEX study is a multi-center, prospective, randomized, controlled trial of 965 continuous ambulatory PD patients in Mexico who were followed for a minimum of two years. The trial was designed to examine the effect of increasing PD small solute clearances a common measure of toxin removal and kidney function on mortality outcomes in patients with ESRD.

Until now, many kidney specialists prescribing PD have believed that increasing small solute clearances would result in better survival. However, ADEMEX researchers
'"/>

Contact: Stephanie Lazor
Stephanie.Lazor@mslpr.com
212-213-77265
Manning Selvage & Lee
18-Apr-2002

Page: 1 2 3 4
Related medicine news :

1. Newly discovered pathway might help in design of cancer drugs
2. Newly identified gene cluster on mouse X chromosome provides insights into fertility
3. Newly discovered virus linked to childhood lung disorders and Kawasaki disease
4. Newly-described route to cancer solves a mystery in lung cancer
5. Newly approved psoriasis drug invented and tested at Univ. of Michigan
6. Newly revised recommendations affirm medicine
7. Newly Updated HIV Treatment Guidelines For Adults And Adolescents Available On The World Wide Web
8. Osteoporosis Drug Evista (Raloxifene) Cuts Newly Diagnosed, Invasive Breast Cancer Risk By More Than 60 Percent
9. For Patients With Advanced Prostate Cancer, Newly Evaluated Drug May Offer Pain Relief And Mild Delay In Disease Progression
10. Treatment guidelines for kids with bipolar disorder published
11. Mount Sinai stroke prevention trial published in JAMA